TROSPIUM CHLORIDE; XANOMELINE TARTRATE | N216158 | BRISTOL-MYERS SQUIBB CO
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Keryx Biopharmaceuticals, Inc et al v. Mylan Pharmaceuticals Inc. 9 patentsANDA 213849, 220394Faricimab | N.D. W. Va. | 2019-03-15 | Terminated 2019-07-31 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$30.35
per ea
Lowest NADAC/Unit
$30.15
per ea
Brand NDCs
4
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00003520056COBENFY STARTER PACK | $30.35 | EA | Brand | — | 2026-01-01 |
| 00003005060COBENFY 50 MG-20 MG CAPSULE | $30.26 | EA | Brand | — | 2026-06-17 |
| 00003012560COBENFY 125 MG-30 MG CAPSULE | $30.25 | EA | Brand | — | 2026-06-17 |
| 00003110060COBENFY 100 MG-20 MG CAPSULE | $30.15 | EA | Brand | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 10238643 | Jul 21, 2030 | — | — | Yes | — | — |
| 10265311 | Jul 21, 2030 | — | — | — | — | |
| 10369143 | Jul 21, 2030 | — | — | — | — | |
| 10369144 | Jul 21, 2030 | — | — | Yes | — | |
| 10695339 | Jul 21, 2030 | — | — | — | — | |
| 10925832 | Sep 27, 2039 | — | — | Yes | — | — |
| 10933020 | Sep 27, 2039 | — | — | Yes | — | |
| 11452692 | Sep 27, 2039 | — | — | — | — | |
| 11471413 | Sep 27, 2039 | — | — | — | — | |
| 11890378 | Sep 27, 2039 | — | — | Yes | — | |
| 12558317 | Oct 29, 2039 | — | — | Yes | — | — |
| Code | Date | Status |
|---|---|---|
| NCE | Sep 26, 2029 | Active |